Business Overview

Neo Performance Materials is a midstream rare earth and specialty metals processor headquartered in Toronto. Not a miner — a value-added converter. The company buys rare earth oxides, concentrates, and scrap metals, then processes them into engineered products for industrial customers. Operations span Estonia, China, Thailand, South Korea, and North America.

Three business lines:

Magnequench (≈42% of revenue, ≈30% of EBITDA). Global leader in bonded NdFeB magnetic powders with an estimated 80% market share (company-claimed; third-party industry reports cite 50-80% depending on scope — high end includes captive production, low end is merchant market only; no independently audited figure exists). The proprietary MQP powder is produced via rapid solidification (melt-spinning) and sold to magnet makers who compression- or injection-mold it into permanent magnets. End markets are auto (EPS motors, seat/wiper/pump motors), appliances, factory automation, and increasingly EV traction. Qualification cycles of 2-3 years create high switching costs — once a powder grade is designed into a motor platform, the OEM doesn't switch. Q3 2025 volumes +21% YoY, bonded magnet shipments at record levels +38% YoY.

Chemicals & Oxides (≈30% of revenue, ≈22% of EBITDA). Rare earth separation (Sillamae, Estonia — 2,000 tpa light RE capacity), emission control catalysts for automotive exhaust, and water treatment chemicals. This segment was transformed in 2023-2024 through divestiture of low-margin Chinese separation assets. EBITDA margin went from 2.8% (2023) to 15.5% (9M 2025) — a turnaround driven by portfolio cleanup and higher RE prices.

Rare Metals (≈30% of revenue, ≈42% of EBITDA). Europe's largest hafnium recycler and one of few non-China gallium recyclers in North America. Also processes indium, rhenium, tantalum, and niobium. Highest-margin segment at ≈29% EBITDA margin. Hafnium margins are normalizing from a 2024 peak (33.2% → 28.6% in 9M 2025). Gallium benefits structurally from Chinese export controls on primary gallium production.

The unit economics are a processing spread. Neo buys raw materials and sells engineered products. Revenue model: Cost + processing margin. This creates asymmetric RE price exposure — higher RE prices benefit C&O (markup on oxides, inventory gains) but don't destroy Magnequench (which is a processing spread) or Rare Metals (which is recycling). Neo benefits more from RE price increases than it suffers from decreases, though pass-through pricing means headline revenue is mechanically linked to commodity prices and can be misleading on its own.

The Estonia sintered magnet plant is the strategic bet. Narva, Estonia: Europe's first industrial-scale sintered NdFeB magnet plant. Phase 1A: 2,000 tpa capacity (approximately 15% of EU demand). Commercial production targeted for mid-2026. EU co-funded via the Just Transition Fund. Bosch has signed a multi-year MOU reserving annual production capacity. Note: an MOU is non-binding — Bosch can walk away without penalty. The commercial risk reduces only when this converts to a definitive supply agreement. Neo is also adding Europe's first dysprosium and terbium (heavy RE) oxide production line at the adjacent Sillamae facility, creating the only vertically integrated mine-to-magnet supply chain in Europe (separation → alloy → sintered magnet, all within 30km).

This converts Neo from a powder/oxide seller to a finished magnet manufacturer — a step change in value capture if execution succeeds.

The China paradox. Neo is positioning as the Western alternative to Chinese RE supply dependence. But as of last disclosure, approximately 30% of revenue came from China, over 45% of the workforce was based in China, and all bonded magnet powder manufacturing (the crown jewel) operated from Chinese facilities (Tianjin, Chuzhou). The Estonia plant addresses this for sintered magnets, but Magnequench bonded powder — the 80% market share business — remains China-manufactured. Neo is simultaneously the solution to and a participant in the China dependency problem. The Korat (Thailand) facility provides partial geographic diversification. These percentages may have shifted post-2023/2024 divestitures of Chinese C&O assets but have not been updated in public disclosures.

Financial Profile

Revenue Trajectory

                    2022        2023        2024        2025E
Revenue (US$)      $640.3M     $571.5M     $475.8M     —
  Magnequench       $277.4M     $213.7M     $176.6M     —
  C&O               $248.0M     $235.9M     $146.5M     —
  Rare Metals       $130.4M     $124.6M     $156.2M     —

Consensus 2025E revenue is $468.9M (4 analysts). Revenue declined 26% from 2022 peak to 2024. Two factors:

1. RE price collapse: NdPr oxide fell from ≈$120/kg (2022) to ≈$55/kg (2024). Since Neo passes through RE costs, revenue fell mechanically even as volumes grew.
2. Strategic divestitures: Sold low-margin Chinese C&O separation assets and the Quapaw, Oklahoma rare metals facility. Revenue fell, margins doubled — intentional.

Volume tells the real story. Magnequench bonded magnet shipments hit records in Q3 2025 (+38% YoY). The business is growing underneath the price noise. Revenue is an unreliable proxy for this company; volumes and margins are the signal.

Margin Structure — The Transformation

                    2022        2023        2024        9M 2025
Adj EBITDA         $79.0M      $37.2M      $64.4M      $55.3M
  Margin            12.3%        6.5%       13.5%       15.4%
Gross Profit       $149.4M     $99.1M     $124.0M        —
  Margin            23.3%       17.3%       26.1%        —

Segment EBITDA Margins:
Magnequench         14.5%        8.7%       14.4%       15.0%
C&O                 11.4%        2.8%        3.3%       15.5%
Rare Metals         18.6%       16.4%       33.2%       28.6%

2023 was the trough. From that inflection, management cut costs, divested low-margin assets, and refocused on high-value segments. Gross margin expanded 880bps in one year (17.3% → 26.1%). C&O was the most dramatic turnaround — from near-zero profitability (2.8%) to a genuine contributor (15.5%).

2025 guidance was raised twice: initial $53-58M → $55-60M → $67-71M. Management has consistently under-promised and over-delivered in this cycle.

Rare Metals margin peaked in 2024 at 33.2% on record hafnium pricing. Normalization is underway. Management guided further compression in 2026.

FCF Conversion

                    2022        2023        2024        2025E
Operating CF       $79.1M        —         $51.5M        —
Capex             ($17.5M)    ($41.7M)   ($80.2M)      ~($31M)
Free Cash Flow     $61.6M     ($6.7M)    ($15.8M)     ~($46M)

2022 was the normal state: $62M FCF on $640M revenue (9.6% FCF margin). 2023-2025 was a heavy investment cycle: $152M cumulative capex, primarily the Estonia sintered magnet plant ($42.5M in 2024 alone) and an emission control catalyst facility ($26.8M in 2024).

The build cycle is ending. 9M 2025 capex was $18.4M, running at approximately a $25M annual rate. Consensus models $22M capex in 2026. As capex normalizes to maintenance levels, FCF conversion should snap back:

Estimated steady-state (post-build):
  Adj EBITDA:        $70-80M
  Maintenance capex: $20-25M
  Working capital:   Neutral (±$5M)
  → FCF:             $45-55M  (≈5-6% yield on $865M EV)

Balance Sheet

                    2022        2023        2024        Q3 2025
Cash               $147.5M     $86.9M     $85.5M      $61.5M
Total Debt          $29.9M     $25.3M     $71.5M      $89.9M
Net Debt          ($117.6M)   ($61.6M)   ($14.0M)     $28.4M
Total Equity       $477.7M    $441.6M    $404.9M     $404.2M
Net Debt/EBITDA    -1.5x      -1.7x      -0.2x       ≈0.4x

Went from net cash $118M to slight net debt $28M — entirely from productive investment. Net debt/EBITDA at 0.4x is conservative. Never took leverage above 0.5x even during peak capex. Balance sheet is clean.

Capital Allocation

                    2022        2023        2024        9M 2025
Dividends          $13.4M      $13.4M     $12.3M      $9.1M
  + Special           —           —       $15.2M        —
Buybacks              —        $19.9M      $2.3M       $3.9M
Capex (growth)     $17.5M      $41.7M     $80.2M      $18.4M

Cumulative 2022-2025 shareholder returns: approximately $89M (regular dividends + special dividend + buybacks). Buybacks at C$8-10 in 2023 appear well-timed. The 2024 special dividend ($15.2M) signaled management confidence that the heavy capex phase was ending.

Competitive Position

Magnequench — Bonded NdFeB Powder (Defensible)

Estimated 50-80% global market share (range depends on scope; company-claimed at upper end, third-party estimates vary). Originally developed by GM/Delco in the 1980s, the Magnequench melt-spinning process was the industry standard for bonded NdFeB powder.

Critical disclosure: the original patents reportedly expired circa 2014. The moat is now held by:

• Process know-how (decades of yield optimization, quality consistency)
• Customer qualification lock-in (2-3 year automotive qualification cycles)
• Low-cost manufacturing footprint (Tianjin, Chuzhou China; Korat Thailand)
• Specification lock-in (powder grades are qualified into specific motor designs)

Competitors include Daido Electronics (Japan, small share) and TDK (Japan, vertically integrated into finished magnets). Chinese producers are growing in capability at the low end. The competitive risk is slow erosion, not sudden disruption — qualification cycles protect, but post-patent-expiry Chinese producers can legally replicate the process.

Estonia Sintered Magnets (Emerging, Unproven)

The sintered NdFeB magnet market is approximately $33B globally, over 92% China-dominated. Neo is entering a market with entrenched competitors:

• Proterial (formerly Hitachi Metals, Japan) — market leader ex-China
• Shin-Etsu (Japan) — #2 ex-China
• VAC/Vacuumschmelze (Germany) — European incumbent, smaller scale

Neo's competitive differentiation is not technology superiority. It is:

1. Vertical integration (Sillamae separation → Narva sintered magnets, 30km apart)
2. Geographic positioning (only European producer with integrated RE supply chain)
3. EU security-of-supply premium (government co-funding, strategic asset classification)
4. Bosch anchor customer (multi-year capacity reservation, reduces commercial risk)
5. Heavy RE capability (Europe's first Dy/Tb production line — the binding constraint)

Key vulnerability: Neo has zero track record in commercial sintered magnet production. Sintered manufacturing is materially different from bonded powder production. Japanese producers have decades of yield optimization. Neo is starting from scratch on the learning curve.

Rare Metals — Hafnium & Gallium Recycling (Defensible)

Europe's largest hafnium recycler. One of few non-China gallium recyclers in North America. Structural advantage: China controls 80%+ of primary gallium and imposed export controls. Neo recycles from scrap — doesn't need Chinese feedstock. As long as China restricts primary gallium, Neo's recycling spread widens.

Cross-Ticker Confirmation of Supply Chain Stress

Multiple independent industrial customers confirm active RE magnet supply disruption:

Regal Rexnord (RRX, $6B industrial) — Three consecutive quarters (Q2-Q4 2025) citing "rare earth magnet availability" headwinds. ≈50bps margin drag. Actively seeking "alternative sources of supply."

Hyliion (HYLN) — 10-K filed Feb 25, 2026: "Currently experiencing limitations on the importation of high strength rare earth magnets that we previously sourced from China... actively pursuing domestic sourcing alternatives, although traditional suppliers often have limited available quantities or are unable to deliver magnets with the strength required for our applications."

Compass Diversified / Arnold Magnetics (CODI) — Q4 2025: "Rare earth magnetics saw meaningful disruption creates compelling long-term opportunity Arnold... geopolitically rare earth supply chain continues rise."

Safran (SAFRY, €80B French aerospace) — Q4 2025: "On rare earth building stocks. Working on alternative supply chains."

WisdomTree (WT) — Q4 2025: Rare earth fund from $100M (Nov) to $700M. Three RE strategic metals funds totaling $1.4B AUM. "Most important themes market."

Arafura (ARAFF) — Jan 2026: NdPr pushed through $100/kg on Asian Metals Index (+80% 12 months). Ex-China pricing benchmark at $10/kg premium. S&P introducing ex-China rare earths pricing index. Independent forecasts of $140-160/kg for non-China supply at market equilibrium.

The demand side of Neo's Estonia thesis is confirmed across independent primary sources. The supply disruption is real, binding, and worsening. Customers cannot get high-strength magnets from China (HYLN 10-K, binding legal disclosure) and cannot find adequate non-China alternatives at required grades.

Management & Governance

Executive Team

Rahim Suleman (CEO & President, since Jul 2023). Was CFO from 2017-2023 before being elevated. Canadian Chartered Accountant, University of Waterloo. Prior: GE Digital Energy, Stackpole International. As CFO he navigated the Oaktree ownership period and Molycorp legacy cleanup. As CEO he architected the transformation — divestitures, Estonia build, strategic pivot to sintered magnets. CFO-turned-CEO is the right profile for a capital allocation inflection.

Jonathan Baksh (CFO, since Jun 2023). CPA, appointed when Suleman was promoted.

Kevin Morris (COO). Long-tenured, operations-focused. Total compensation approximately C$655K.

Board

Edgar Lee (Chair, since Jun 2025). Founded and managed $6B Strategic Credit Strategy at Oaktree Capital Management. Director since 2017. Institutional-grade capital allocation discipline.

Paul Mascarenas, OBE (New, 2025). Former Ford Motor Company CTO/VP (32 years). Boards: ON Semiconductor, US Steel, Shyft Group. Brings direct auto/EV customer perspective — the market Neo's Estonia plant sells into.

Jonathan Evans (New, 2025). CEO of Lithium Americas. Critical minerals operations experience.

Hua Du. 25 years in Asian/global markets. 11 years as President at a major global RE company. China/RE market intelligence.

Board quality is above average for a $900M company.

Insider Activity

Open market purchases (not grants/exercises):

Suleman has purchased approximately C$700K+ in open market shares during 2025 at prices ranging from C$7 to C$12. For a CEO with total compensation likely under C$1.2M, this is meaningful skin in the game — steady accumulation at multiple price points, not a one-time publicity purchase. Mascarenas bought ~C$90K within weeks of joining the board — small dollar amount but directionally significant.

No insider selling by management. The only major disposition was Wyloo Consolidated (Andrew Forrest's vehicle) which acquired a 20% stake in Feb 2025 for C$72.1M (~C$8.63/share), then sold the entire position in Oct 2025 via block trade at ~C$14.25/share for C$118M (65% return in 8 months). Two interpretations: (1) financial trade — Wyloo pivoted capital toward direct mine ownership (Hastings/Yangibana RE JV), a strategic reallocation not reflecting on Neo; (2) a sophisticated strategic buyer saw full value at C$14.25 and chose to exit entirely rather than hold for the Estonia upside, implying limited further upside from that level. The stock has since doubled to C$28, so interpretation (1) appears correct in hindsight — but the fact that a knowledgeable holder exited entirely is worth noting.

Capital Allocation Track Record

Divestitures: Correctly identified that competing with Chinese separators on cost was losing. Sold low-margin Chinese C&O assets and Quapaw facility. Revenue fell, margins doubled. Well-executed.

Estonia investment: $100M+ committed to greenfield facility, EU co-funded, completed in 500 days, Bosch offtake secured before commercial production. Timeline was prescient — broke ground well before China's Oct 2024 export controls made "Western RE supply chain" a headline.

Balance sheet: Never exceeded 0.5x net debt/EBITDA during peak capex cycle. Conservative.

Shareholder returns: $89M returned over 3 years (dividends, special, buybacks) while simultaneously investing $140M+ in growth. The 2024 special dividend was a clear confidence signal.

Factor Profile

Regression Results (1-Year, Daily)

MODEL: NOPMF = α + β₁(SPY) + β₂(REMX) + β₃(MTUM) + β₄(IWM)

Factor      β          Single-Factor R²
───────────────────────────────────────────
SPY       -0.35        14.3%
REMX      +0.38        15.4%
MTUM      +0.79        15.2%
IWM       +0.35        14.8%

Combined R²:     22.0%
Idio Variance:   78.0%   (above 75% target)

α (annual):     +97.2%
Idio Vol:        57.9%
Idio Sharpe:     1.68

Interpretation

78% idiosyncratic on a full-year basis — but declining. The full-period number masks a deteriorating trend. Rolling 60-day analysis shows idio variance fell from 86% (early 2025) to approximately 70% recently. The operative number for sizing is 70%, which fails the 75% Paleologo threshold. The stock is increasingly a factor trade, not a pure company story.

Neo is the least sector-correlated among RE peers:

Ticker     Idio vs REMX    β_REMX
NOPMF      84.6%           0.56      Loosely tied to sector
LYSCF      69.8%           0.76      More sector-driven
MP         71.0%           1.14      Levered sector play

This makes sense — Neo is a midstream processor, not a miner. Its returns are driven by processing spreads, Estonia execution, and hafnium/gallium margins, not just RE commodity prices.

The negative SPY beta (-0.35) is geopolitical hedge behavior. When markets sell off on US-China tension, RE supply chain plays rally. This is a portfolio diversification feature.

Momentum loading is the primary factor risk. β_MTUM = +0.79 in the full model. With +262% trailing 1Y return and RSI 88, NOPMF is accumulating significant momentum exposure. Rolling analysis shows idio declining from 86% (early 2025) to 70% (recent), while momentum beta rose from +0.06 to +0.84.

The stock went from a pure company story (86% idio, zero sector correlation) to an increasingly factor-contaminated trade. The market has reclassified NOPMF from "obscure Canadian processor" to "Western RE supply chain theme stock." That re-classification IS the multiple expansion — and it means returns increasingly depend on the sector narrative holding, not just company execution.

Edge Audit

Forward Expectations Gap Analysis

What the Market is Paying

                        2025E       2026E       2027E
EV/EBITDA              12.3x       11.9x       10.6x
P/E                    113x        56x         36x
EV/Revenue             1.85x       1.77x       1.59x
FCF Yield             -5.3%       +4.1%       +3.1%

12x EV/EBITDA is a growth multiple for specialty materials (historical Neo average: 6-8x; specialty materials peers: 8-10x). The stock trades above the mean analyst price target of C$25.89.

Consensus Estimates (4 Analysts, USD)

                    2025E       2026E       2027E
Revenue            $468.9M     $488.0M     $542.7M
  YoY growth        -1.4%       +4.1%      +11.2%
EBITDA              $70.4M      $72.7M      $81.9M
  Margin            15.0%       14.9%       15.1%
Net Income           $7.4M      $15.0M      $23.2M
Capex               $31.1M      $21.7M      $23.7M
FCF                -$45.7M     $35.1M      $26.7M

What Current Price Requires

At 12x EV/EBITDA (growth):   ≈$72M EBITDA  →  2026E consensus delivers
At 10x (fair specialty):     ≈$87M EBITDA  →  Needs 2027E + small beat
At 8x (historical average):  ≈$108M EBITDA →  Needs Estonia at scale

The price is justified on consensus at 12x. The question is whether 12x is sustainable for a company that historically traded at 6-8x, and whether consensus itself is correct.

Identified Gaps

Gap 1: Estonia revenue is barely in consensus. 2026E revenue is $488M, only $19M above 2025E, implying negligible Estonia contribution. Management targets commercial production mid-2026 with Bosch offtake (MOU, non-binding). At even a modest 500-tonne H2 2026 run rate at $70/kg: +$35M revenue, +$8M EBITDA (assuming ≈22% margin — this is a mature-state assumption; Year 1 yields at a greenfield plant will likely be lower, possibly 10-15% EBITDA margin until the learning curve is climbed). At 1,000 tonnes: +$70M revenue, +$15M EBITDA at mature margins. Consensus appears to model little to none of this.

Gap 2: RE pricing isn't fully reflected. Consensus assumes flat ≈15% EBITDA margins through 2027. NdPr is at $100/kg (+80% YoY). Ex-China pricing benchmarks are emerging at $110-160/kg. If the ex-China premium holds, C&O margins could sustain 18-25% versus the ≈15% consensus models.

Gap 3: Hafnium normalization may be under-modeled. Rare Metals was 42% of 9M 2025 EBITDA at 29% margins. If hafnium prices compress another 20-30% in 2026, the segment could give back $5-10M EBITDA. This partially offsets gains elsewhere and may not be fully reflected in either direction.

Gap 4: The FCF inflection. From -$46M (2025E) to +$35M (2026E) is an $81M swing in one year. If Estonia contributes modestly, 2026 FCF could reach $40-50M versus the $35M consensus.

Gap 5: Analyst coverage is stale. The most recent formal target was Stifel at C$8 in March 2024 — before China export controls escalated, before Estonia opened, before the RE price spike. The stock has overshot every published target. When analysts update (likely around March 17 earnings), targets will move materially. The revision cycle has not yet occurred.

Management vs. Consensus

Key Risks

Estonia execution (High). Neo has zero commercial track record in sintered magnet manufacturing. Sintered NdFeB production requires different expertise than bonded powder. Japanese producers have decades of yield optimization. If the ramp is slower than targeted, costlier, or quality doesn't meet automotive PPAP standards, the growth thesis collapses and the multiple compresses.

China supply chain exposure (High). Despite the "Western supply chain" narrative, 30% of revenue still comes from China, 45%+ of employees are in China, and all bonded magnet manufacturing facilities are located in China (Tianjin, Chuzhou). If China imposes export controls on bonded NdFeB powders (not just raw RE), Neo's crown jewel business faces disruption. The company is simultaneously the solution to Western RE dependency and exposed to the same geopolitical forces that create demand for that solution.

Russian feedstock dependency (Medium-High). The Sillamae separation plant in Estonia has historically sourced a significant portion of RE feedstock from a Russian supplier. Alternative sources are under development (Energy Fuels in the US, Australian projects) but not fully secured. If EU sanctions expand to cover RE materials, Sillamae's feedstock supply is at risk.

Multiple compression (Medium-High). The stock has re-rated from 6-8x historical EV/EBITDA to 12x. This premium prices in Estonia + China RE tailwinds. If either disappoints — Estonia ramp delays, or China lifts export controls — the multiple reverts. At 8x on 2027E EBITDA, the stock is worth approximately C$18 (35% below current).

Auto end-market concentration (Medium). Over 50% of revenue is tied to the automobile sector across all three segments (Magnequench powders for auto motors, C&O catalysts for auto exhaust). An auto downturn hits all segments simultaneously. This is cyclical risk disguised by the three-segment structure.

Momentum tail risk (Medium). +262% in one year, RSI 88. Momentum beta has risen from +0.06 to +0.84. Idio variance declined from 86% to 70%. If the RE sector narrative reverses or momentum crashes (as in 2009, 2016), NOPMF could draw down 40-50% independent of fundamental performance.

Patent expiry (Medium, long-term). Magnequench patents expired in 2014. The 80% market share is now held by process know-how and qualification lock-in, not legal protection. Chinese producers can legally replicate the technology. Erosion timeline is years (qualification cycles protect), but the moat is slowly degrading.

EU EV demand destruction (Medium). EU tariffs on Chinese EVs (up to 45.3%) could reduce total EU EV sales volumes in the near term. Fewer EVs sold in Europe means fewer traction motor magnets needed — regardless of where those magnets are made. The tariffs are framed as a tailwind for Western supply chains, but the volume destruction effect on Neo's addressable market is the other side of that coin.

Hafnium normalization (Medium). Rare Metals was the highest-margin segment in 2024-2025 on exceptional hafnium pricing. As pricing normalizes, segment EBITDA could compress $5-15M from recent run rates.

Phase 1B capital requirements (Medium). Phase 1A (2,000 tpa) is built. Phase 1B expansion to 5,000 tpa will require additional capital. If funded from operations (steady-state FCF $45-55M), it's manageable. If timed alongside weak FCF or an auto downturn, an equity raise at 41.6M shares outstanding creates meaningful dilution.

Downside Scenario

What does EBITDA look like if multiple risks hit simultaneously?

                            Base (consensus)    Bear case
Magnequench EBITDA                $30M           $25M  (auto downturn -15% vol)
C&O EBITDA                        $22M           $12M  (RE prices drop to $70/kg)
Rare Metals EBITDA                $28M           $18M  (hafnium -35% from 2025)
Corporate                        ($7M)          ($7M)
Estonia contribution               $0             $0  (ramp delayed to 2027)
─────────────────────────────────────────────────────────────
Total EBITDA                      $73M           $48M

At 8x (historical multiple):     EV $384M → equity C$14/share (-50%)
At 10x:                          EV $480M → equity C$18/share (-36%)

This is not a prediction — it's the floor. Hafnium normalization + auto weakness + Estonia delay + RE price reversal is a plausible compound scenario, not a tail event. Each component has independent probability. The market at 12x on $73M is pricing none of them.

Sourcing Limitations

Neo Performance Materials files under SEDAR+ (Canada), not with the SEC. We cannot independently verify financial claims, segment data, or insider transactions through EDGAR tools. Financial data in this report was sourced from company press releases, investor presentations, and third-party aggregations of SEDAR filings (Simply Wall St, MarketScreener, Yahoo Finance). Cross-ticker counterparty evidence (HYLN 10-K, RRX/CODI/SAFRY transcripts) was verified through EDGAR and our transcript database. Certain claims — the 80% market share figure, patent expiry date, China revenue and workforce percentages — originate from company IR materials and/or third-party analysis and could not be independently verified against primary regulatory filings.

What to Watch

March 17, 2026 — Q4 2025 earnings. Management will report FY2025 results and likely provide 2026 guidance. Key items: (1) FY2025 EBITDA relative to $67-71M guidance range, (2) any 2026 EBITDA or revenue guidance, (3) Estonia ramp-up specifics and Bosch volume commitments, (4) Dy/Tb heavy RE line commissioning status, (5) hafnium pricing commentary.

Estonia PPAP qualification (H1 2026). Production Part Approval Process for automotive sintered magnets. If qualification samples are accepted by Bosch and other customers, commercial volumes follow. If rejected or delayed, the ramp timeline extends and the thesis weakens.

RE pricing trajectory. NdPr at $100/kg is supportive. Below $80/kg, C&O margin gains reverse. Above $120/kg, the ex-China premium thesis strengthens. The S&P ex-China pricing index (under development) is a structural catalyst — it formalizes the non-China supply premium.

China export control policy. Announcement 18 (7 heavy RE elements including Dy and Tb) was never suspended despite the November 2025 headline suspension. Any expansion of controls to processed magnets or bonded powders directly impacts Neo — positively (demand for non-China supply) and negatively (Neo's own Chinese manufacturing). Any lifting of controls deflates the entire sector.

Analyst coverage updates. Only 4 analysts, all targets stale (most recent formal target: C$8 in March 2024). Coverage initiation or target revisions will move the stock, likely upward from published levels but potentially below current price.

Insider activity. CEO Suleman has been buying steadily. Continued purchases at current elevated prices would be a strong signal. Any insider selling by management (versus directors or strategic holders) would be a material negative signal.

Hafnium spot pricing. Published by metal bulletin / Fastmarkets. Downside risk to Rare Metals EBITDA if prices continue to normalize.

4 analysts cover this stock. Coverage is thin. The last formal price target (Stifel, C$8) is from March 2024. The stock has quadrupled since. Either analysts are massively behind, or the market is pricing optionality they can't model. March 17 earnings will provide the first data point to distinguish between these two interpretations.

LR signal reflects the gap between what cross-ticker primary sources confirm (binding RE magnet supply disruption across multiple industrial 10-Ks and transcripts) versus what consensus models (modest 4% revenue growth, flat margins). The counterparty evidence is strong and sourced from binding legal filings — HYLN's 10-K disclosure that they cannot import high-strength magnets is not marketing. However, the +262% trailing return and 12x multiple already embed significant RE tailwind expectations. The primary source evidence is more bullish than consensus, but the stock has already moved substantially.